| Mitochondrial genome-knockout cells demonstrate a dual mechanism of action for the electron transport complex I inhibitor mycothiazole. | |
| | |
MedLine Citation:
|
PMID: 22690150 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Mycothiazole, a polyketide metabolite isolated from the marine sponge Cacospongia mycofijiensis, is a potent inhibitor of metabolic activity and mitochondrial electron transport chain complex I in sensitive cells, but other cells are relatively insensitive to the drug. Sensitive cell lines (IC(50) 0.36-13.8 nM) include HeLa, P815, RAW 264.7, MDCK, HeLa S3, 143B, 4T1, B16, and CD4/CD8 T cells. Insensitive cell lines (IC(50) 12.2-26.5 μM) include HL-60, LN18, and Jurkat. Thus, there is a 34,000-fold difference in sensitivity between HeLa and HL-60 cells. Some sensitive cell lines show a biphasic response, suggesting more than one mechanism of action. Mitochondrial genome-knockout ρ(0) cell lines are insensitive to mycothiazole, supporting a conditional mitochondrial site of action. Mycothiazole is cytostatic rather than cytotoxic in sensitive cells, has a long lag period of about 12 h, and unlike the complex I inhibitor, rotenone, does not cause G(2)/M cell cycle arrest. Mycothiazole decreases, rather than increases the levels of reactive oxygen species after 24 h. It is concluded that the cytostatic inhibitory effects of mycothiazole on mitochondrial electron transport function in sensitive cell lines may depend on a pre-activation step that is absent in insensitive cell lines with intact mitochondria, and that a second lower-affinity cytotoxic target may also be involved in the metabolic and growth inhibition of cells. |
| | |
Authors:
|
Kirsten J Meyer; A Jonathan Singh; Alanna Cameron; An S Tan; Dora C Leahy; David O'Sullivan; Praneta Joshi; Anne C La Flamme; Peter T Northcote; Michael V Berridge; John H Miller |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-04-16 |
Journal Detail:
|
Title: Marine drugs Volume: 10 ISSN: 1660-3397 ISO Abbreviation: Mar Drugs Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-06-12 Completed Date: 2012-11-26 Revised Date: 2013-03-05 |
Medline Journal Info:
|
Nlm Unique ID: 101213729 Medline TA: Mar Drugs Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 900-17 Citation Subset: IM |
Affiliation:
|
Centre for Biodiscovery and Schools of Biological Sciences, Victoria University of Wellington, PO Box 600, Wellington, New Zealand. kirstenjoymeyer@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Aquatic Organisms / chemistry, metabolism Cell Cycle / drug effects Cell Line Cell Line, Tumor Cell Proliferation / drug effects Cell Survival / drug effects Dogs Electron Transport Complex I / antagonists & inhibitors* Genome, Mitochondrial* HL-60 Cells HeLa Cells Humans Jurkat Cells Mice Mitochondria / drug effects*, genetics, metabolism* Porifera / chemistry, metabolism Reactive Oxygen Species / metabolism Thiazoles / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Reactive Oxygen Species; 0/Thiazoles; 0/mycothiazole; EC 1.6.5.3/Electron Transport Complex I |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 ...
Next Document: Structural characterization and anti-HSV-1 and HSV-2 activity of glycolipids from the marine algae O...